Deep vein thrombosis future or investigational therapies: Difference between revisions
Jump to navigation
Jump to search
No edit summary |
No edit summary |
||
| Line 6: | Line 6: | ||
* Primary Outcome Measures: Composite of VTE (DVT and/or PE) and VTE death | * Primary Outcome Measures: Composite of VTE (DVT and/or PE) and VTE death | ||
* Secondary Outcome Measures: Number of patients with symptomatic VTE | * Secondary Outcome Measures: Number of patients with symptomatic VTE | ||
* Estimated Enrollment: | * Estimated Enrollment: 6850 | ||
* Study Start Date: | * Study Start Date: March 2012 | ||
* Estimated Study Completion Date: December 2014 | * Estimated Study Completion Date: December 2014 | ||
* {| | * {| | ||
Revision as of 02:01, 20 June 2012
Ongoing Research
Phase 3 Trials
Acute Medically Ill venous thromboembolism (VTE) Prevention With Extended Duration Betrixaban Study (The APEX Study): Sponsored by Portola Pharmaceuticals
- Primary Outcome Measures: Composite of VTE (DVT and/or PE) and VTE death
- Secondary Outcome Measures: Number of patients with symptomatic VTE
- Estimated Enrollment: 6850
- Study Start Date: March 2012
- Estimated Study Completion Date: December 2014
- {|
- |-
- {|Arms
Efficacy and Safety Study of Apixaban for Extended Treatment of Deep Vein Thrombosis or Pulmonary Embolism: Sponsored by Bristol-Myers Squibb and Pfizer [1]
- Primary Outcome Measures: Venous Thromboembolic Recurrence or Death
- Secondary Outcome Measures: Bleeding
- Estimated Enrollment: 2,430 patients
- Study Start Date: May 2008
- Estimated Study Completion Date: August 2012